412 related articles for article (PubMed ID: 21829025)
21. Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomized, prospective trial.
Kanematsu T; Koyanagi N; Matsumata T; Kitano S; Takenaka K; Sugimachi K
Surgery; 1988 Sep; 104(3):482-8. PubMed ID: 2842882
[TBL] [Abstract][Full Text] [Related]
22. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
[TBL] [Abstract][Full Text] [Related]
23. Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma.
Ishikawa T; Michitaka I; Kamimura H; Higuchi K; Kubota T; Seki K; Ohta H; Yoshida T; Kamimura T
Hepatogastroenterology; 2009; 56(94-95):1491-5. PubMed ID: 19950815
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M
Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937
[TBL] [Abstract][Full Text] [Related]
25. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study.
Park JG; Tak WY; Park SY; Kweon YO; Jang SY; Lee YR; Bae SH; Jang JY; Kim DY; Lee JS; Suk KT; Kim IH; Lee HJ; Chung WJ; Jang BK; Suh JI; Heo J; Lee WK
Medicine (Baltimore); 2017 Jun; 96(24):e6580. PubMed ID: 28614215
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis.
Chen L; Chen Y; Wang X; Li H; Zhang H; Gong J; Shen S; Yin W; Hu H
Nutr J; 2015 Jul; 14():67. PubMed ID: 26155840
[TBL] [Abstract][Full Text] [Related]
28. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Niinomi T; Ito T; Hasegawa R; Ando Y; Yamamoto K; Tanaka T
Hepatol Res; 2014 Mar; 44(3):288-95. PubMed ID: 23607436
[TBL] [Abstract][Full Text] [Related]
29. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
30. Oral supplementation with carbohydrate- and branched-chain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection.
Okabayashi T; Iyoki M; Sugimoto T; Kobayashi M; Hanazaki K
Amino Acids; 2011 Apr; 40(4):1213-20. PubMed ID: 20852905
[TBL] [Abstract][Full Text] [Related]
31. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?
Charlton M
Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):72-3. PubMed ID: 16456570
[No Abstract] [Full Text] [Related]
32. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis.
Yeh CN; Chen MF; Lee WC; Jeng LB
J Surg Oncol; 2002 Dec; 81(4):195-202. PubMed ID: 12451624
[TBL] [Abstract][Full Text] [Related]
33. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
34. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
[TBL] [Abstract][Full Text] [Related]
35. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.
Arrieta O; Rodriguez-Diaz JL; Rosas-Camargo V; Morales-Espinosa D; Ponce de Leon S; Kershenobich D; Leon-Rodriguez E
Cancer; 2006 Oct; 107(8):1852-8. PubMed ID: 16967451
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized controlled study of short-term perioperative oral nutrition with branched chain amino acids in patients undergoing liver surgery.
Ishikawa Y; Yoshida H; Mamada Y; Taniai N; Matsumoto S; Bando K; Mizuguchi Y; Kakinuma D; Kanda T; Tajiri T
Hepatogastroenterology; 2010; 57(99-100):583-90. PubMed ID: 20698232
[TBL] [Abstract][Full Text] [Related]
37. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels.
Bianchi GP; Marchesini G; Zoli M; Abbiati R; Ferrario E; Fabbri A; Pisi E
Hepatogastroenterology; 1992 Oct; 39(5):443-6. PubMed ID: 1459529
[TBL] [Abstract][Full Text] [Related]
38. Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
Kawaguchi T; Izumi N; Charlton MR; Sata M
Hepatology; 2011 Sep; 54(3):1063-70. PubMed ID: 21563202
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.
Kobayashi M; Ikeda K; Arase Y; Suzuki Y; Suzuki F; Akuta N; Hosaka T; Murashima N; Saitoh S; Someya T; Tsubota A; Kumada H
J Gastroenterol; 2008; 43(1):63-70. PubMed ID: 18297438
[TBL] [Abstract][Full Text] [Related]
40. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.
Nkontchou G; Aout M; Mahmoudi A; Roulot D; Bourcier V; Grando-Lemaire V; Ganne-Carrie N; Trinchet JC; Vicaut E; Beaugrand M
Cancer Prev Res (Phila); 2012 Aug; 5(8):1007-14. PubMed ID: 22525582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
